SVB Wealth LLC Lowers Stake in Danaher Co. (NYSE:DHR)

SVB Wealth LLC lowered its stake in shares of Danaher Co. (NYSE:DHR) by 4.3% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 50,823 shares of the conglomerate’s stock after selling 2,261 shares during the period. SVB Wealth LLC’s holdings in Danaher were worth $12,698,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after buying an additional 4,163,657 shares during the period. Wellington Management Group LLP lifted its position in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the last quarter. Capital International Investors lifted its position in shares of Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after purchasing an additional 1,334,781 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Danaher during the 4th quarter worth $1,752,382,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on DHR shares. Bank of America lifted their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Leerink Partners lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Wells Fargo & Company started coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Danaher in a report on Friday. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $278.94.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.6 %

Shares of DHR stock traded up $1.49 during mid-day trading on Friday, reaching $266.20. The company’s stock had a trading volume of 3,324,729 shares, compared to its average volume of 2,790,567. The company’s 50 day simple moving average is $261.30 and its 200-day simple moving average is $255.73. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $197.17 billion, a PE ratio of 45.12, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue was down 2.9% on a year-over-year basis. During the same period last year, the business earned $2.05 EPS. On average, research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.